

Interactions between PD-1 and PD-L1 promote tolerance signal

Nature Immunology

10, 1185-1192

DOI: [10.1038/ni.1790](https://doi.org/10.1038/ni.1790)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Plasma Fibrinogen Levels and the Clinical Course of Acute Myocardial Infarction. <i>Angiology</i> , 1983, 34, 693-698.	0.8	22
2	Is Antigen Specificity of Autoreactive T Cells the Key to Islet Entry?. <i>Immunity</i> , 2009, 31, 534-536.	6.6	8
3	Urinary Cell Levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and Acute Rejection of Human Renal Allografts. <i>Transplantation</i> , 2010, 90, 1381-1387.	0.5	59
4	Dynamics of dendritic cell-T cell interactions: a role in T cell outcome. <i>Seminars in Immunopathology</i> , 2010, 32, 227-238.	2.8	30
5	Lower expression levels of the programmed death 1 receptor on CD4+CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 1702-1711.	6.7	55
6	The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1870-1880.	6.7	126
7	Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?. <i>Immunity</i> , 2010, 32, 488-499.	6.6	150
8	Partial restoration of T cell function in aged mice by <i>in vitro</i> blockade of the PD-1/SPD-L1 pathway. <i>Aging Cell</i> , 2010, 9, 785-798.	3.0	105
9	The PD-1 pathway in tolerance and autoimmunity. <i>Immunological Reviews</i> , 2010, 236, 219-242.	2.8	1,902
10	PD-1 signalling in CD4 ⁺ T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance. <i>Immunology</i> , 2010, 130, 92-102.	2.0	30
11	Mechanisms maintaining peripheral tolerance. <i>Nature Immunology</i> , 2010, 11, 21-27.	7.0	373
12	Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival. <i>Transplant International</i> , 2010, 23, 1259-1270.	0.8	23
13	A Novel Technique for the In Vivo Imaging of Autoimmune Diabetes Development in the Pancreas by Two-Photon Microscopy. <i>PLoS ONE</i> , 2010, 5, e15732.	1.1	60
14	Mice Producing Less Reactive Oxygen Species Are Relatively Resistant to Collagen Glycopeptide Vaccination against Arthritis. <i>Journal of Immunology</i> , 2010, 185, 2701-2709.	0.4	9
15	Role of antigen persistence and dose for CD4 ⁺ T-cell exhaustion and recovery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20453-20458.	3.3	119
16	Congenetic Mesenchymal Stem Cell Therapy Reverses Hyperglycemia in Experimental Type 1 Diabetes. <i>Diabetes</i> , 2010, 59, 3139-3147.	0.3	139
17	Making antigen invisible: a coinhibitory molecule regulates the interaction between T cells and dendritic cells. <i>Expert Review of Vaccines</i> , 2010, 9, 243-247.	2.0	3
18	PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4275-4280.	3.3	1,602

#	ARTICLE	IF	CITATIONS
19	T Follicular Helper Cells During Immunity and Tolerance. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 92, 207-248.	0.9	43
20	Roles for TGF- β 2 and Programmed Cell Death 1 Ligand 1 in Regulatory T Cell Expansion and Diabetes Suppression by Zymosan in Nonobese Diabetic Mice. <i>Journal of Immunology</i> , 2010, 185, 2754-2762.	0.4	26
21	Killer artificial antigen-presenting cells: the synthetic embodiment of a "guided missile". <i>Immunotherapy</i> , 2010, 2, 539-550.	1.0	24
22	PD-1 on Immature and PD-1 Ligands on Migratory Human Langerhans Cells Regulate Antigen-Presenting Cell Activity. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2222-2230.	0.3	28
23	Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines. <i>Immunotherapy</i> , 2010, 2, 561-574.	1.0	19
24	Approaches for immunological tolerance induction to stem cell-derived cell replacement therapies. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 435-448.	1.3	25
26	Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1. <i>Cell</i> , 2011, 146, 772-784.	13.5	1,304
27	Tolerogenic dendritic cells and their role in transplantation. <i>Seminars in Immunology</i> , 2011, 23, 252-263.	2.7	153
28	Immune intervention with T regulatory cells: Past lessons and future perspectives for type 1 diabetes. <i>Seminars in Immunology</i> , 2011, 23, 182-194.	2.7	46
29	Follicular Helper CD4 T Cells (T _{FH}). <i>Annual Review of Immunology</i> , 2011, 29, 621-663.	9.5	2,391
30	LAG-3, TGF- β 2, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. <i>Blood</i> , 2011, 117, 5532-5540.	0.6	38
31	Mesenchymal Stem Cells: Immunology and Therapeutic Benefits. , 0, , .		4
32	Pharmacological manipulation of dendritic cells in the pursuit of transplantation tolerance. <i>Current Opinion in Organ Transplantation</i> , 2011, 16, 372-378.	0.8	15
33	The Present and Future of Peptide Vaccines for Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 343-350.	1.0	248
34	Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. <i>Clinical and Experimental Immunology</i> , 2011, 165, 243-250.	1.1	34
35	Oestrogen-mediated protection of experimental autoimmune encephalomyelitis in the absence of Foxp3+ regulatory T cells implicates compensatory pathways including regulatory B cells. <i>Immunology</i> , 2011, 132, 340-347.	2.0	48
36	Intrinsic and extrinsic control of peripheral T cell tolerance by costimulatory molecules of the CD28/B7 family. <i>Immunological Reviews</i> , 2011, 241, 180-205.	2.8	330
37	Mechanisms of tolerance. <i>Immunological Reviews</i> , 2011, 241, 5-19.	2.8	95

#	ARTICLE	IF	CITATIONS
38	The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. <i>Nature Reviews Immunology</i> , 2011, 11, 852-863.	10.6	609
39	The role of the PD-1 pathway in autoimmunity and peripheral tolerance. <i>Annals of the New York Academy of Sciences</i> , 2011, 1217, 45-59.	1.8	290
40	Selective CD28 Blockade Attenuates Acute and Chronic Rejection of Murine Cardiac Allografts in a CTLA-4-Dependent Manner. <i>American Journal of Transplantation</i> , 2011, 11, 1599-1609.	2.6	81
41	Critical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in Type I Diabetes. <i>Autoimmunity Reviews</i> , 2011, 11, 104-111.	2.5	20
42	Mesenchymal Stem Cells: Mechanisms of Inflammation. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2011, 6, 457-478.	9.6	715
43	Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. <i>European Journal of Immunology</i> , 2011, 41, 2217-2228.	1.6	69
44	The Status of PD-L1 (B7-H1) on tolerogenic APCs. <i>European Journal of Immunology</i> , 2011, 41, 286-290.	1.6	34
45	PD-L1 blockade overrides <i>Salmonella typhimurium</i> -mediated diabetes prevention in NOD mice: No role for Tregs. <i>European Journal of Immunology</i> , 2011, 41, 2966-2976.	1.6	12
46	PD-L1 co-stimulation contributes to ligand-induced T cell receptor downmodulation on CD8 ⁺ T cells. <i>EMBO Molecular Medicine</i> , 2011, 3, 581-592.	3.3	234
47	Intravital Imaging Reveals Limited Antigen Presentation and T Cell Effector Function in Mycobacterial Granulomas. <i>Immunity</i> , 2011, 34, 807-819.	6.6	226
48	Cell Surface Signaling Molecules in the Control of Immune Responses: A Tide Model. <i>Immunity</i> , 2011, 34, 466-478.	6.6	152
49	Chronic Infections Capture Little Attention of the Masses. <i>Immunity</i> , 2011, 34, 699-701.	6.6	0
50	Embryonic Stem Cell-Derived Hematopoietic Stem Cells: Challenges in Development, Differentiation, and Immunogenicity. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1621-1637.	1.0	11
51	Fighting with the Enemys Weapons? The Role of Costimulatory Molecules in HIV. <i>Current Molecular Medicine</i> , 2011, 11, 172-196.	0.6	4
52	Therapeutic targeting of B7-H1 in breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 1211-1225.	1.5	36
53	The PDL1-PD1 Axis Converts Human T _H 1 Cells into Regulatory T Cells. <i>Science Translational Medicine</i> , 2011, 3, 111ra120.	5.8	370
54	Transfer of Regulatory Properties from Tolerogenic to Proinflammatory Dendritic Cells via Induced Autoreactive Regulatory T Cells. <i>Journal of Immunology</i> , 2011, 187, 6357-6364.	0.4	52
55	Emerging antibody combinations in oncology. <i>MAbs</i> , 2011, 3, 338-351.	2.6	27

#	ARTICLE	IF	CITATIONS
56	Tolerance Induced by Apoptotic Antigen-Coupled Leukocytes Is Induced by PD-L1+ and IL-10-Producing Splenic Macrophages and Maintained by T Regulatory Cells. <i>Journal of Immunology</i> , 2011, 187, 2405-2417.	0.4	182
57	The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	118
58	Hodgkin Disease and the Role of the Immune System. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 176-186.	0.3	34
59	Layers of dendritic cell-mediated T cell tolerance, their regulation and the prevention of autoimmunity. <i>Frontiers in Immunology</i> , 2012, 3, 183.	2.2	55
60	Inflammation and type one diabetes. <i>International Immunology</i> , 2012, 24, 339-346.	1.8	52
61	Current and Future Immunomodulation Strategies to Restore Tolerance in Autoimmune Diseases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a007542-a007542.	2.3	59
62	Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape. <i>Cancer Research</i> , 2012, 72, 917-927.	0.4	1,311
63	CD4+ Type II NKT Cells Mediate ICOS and Programmed Death-1-Dependent Regulation of Type 1 Diabetes. <i>Journal of Immunology</i> , 2012, 188, 3138-3149.	0.4	55
64	IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12668-12673.	3.3	119
65	Anti-IL-7 receptor-1 reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12674-12679.	3.3	116
66	Antigen-Specific Therapeutic Approaches in Type 1 Diabetes. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007773-a007773.	2.9	40
67	Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2012, 51, 1188-1197.	0.9	52
68	Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interaction. <i>Reviews on Recent Clinical Trials</i> , 2012, 7, 10-23.	0.4	31
69	Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal. <i>Blood</i> , 2012, 120, 4560-4570.	0.6	37
70	Functional immunoinaging: the revolution continues. <i>Nature Reviews Immunology</i> , 2012, 12, 858-864.	10.6	77
71	Role of the PD-1 Pathway in the Immune Response. <i>American Journal of Transplantation</i> , 2012, 12, 2575-2587.	2.6	348
72	Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. <i>Nature Biotechnology</i> , 2012, 30, 1217-1224.	9.4	351
73	Overexpression of Programmed Death Ligand 1 in Dendritic Cells Inhibits Allogeneic Lymphocyte Activation in Mice. <i>Journal of Surgical Research</i> , 2012, 176, e79-e87.	0.8	8

#	ARTICLE	IF	CITATIONS
74	Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. <i>Journal of Experimental Medicine</i> , 2012, 209, 1201-1217.	4.2	864
75	Tumor-Associated Antigen Expressing <i>Listeria monocytogenes</i> Induces Effective Primary and Memory T-Cell Responses Against Hepatic Colorectal Cancer Metastases. <i>Annals of Surgical Oncology</i> , 2012, 19, 597-607.	0.7	26
76	HPK1 as a novel target for cancer immunotherapy. <i>Immunologic Research</i> , 2012, 54, 262-265.	1.3	36
77	Nerve-Driven Immunity. , 2012, , .		18
78	The Role of Coinhibitory Signaling Pathways in Transplantation and Tolerance. <i>Frontiers in Immunology</i> , 2012, 3, 47.	2.2	55
79	Pathogenic Mechanisms in Type 1 Diabetes: The Islet is Both Target and Driver of Disease. <i>Review of Diabetic Studies</i> , 2012, 9, 148-168.	0.5	55
80	The blockade of immune checkpoints in cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2012, 12, 252-264.	12.8	10,874
81	Safety and Activity of Anti-“PD-L1 Antibody in Patients with Advanced Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2455-2465.	13.9	6,820
82	A Decade of Imaging Cellular Motility and Interaction Dynamics in the Immune System. <i>Science</i> , 2012, 336, 1676-1681.	6.0	371
83	IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction “ A comparative study of human clinical-applicable DC. <i>Clinical Immunology</i> , 2012, 142, 332-342.	1.4	238
84	Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. <i>BMC Medicine</i> , 2012, 10, 3.	2.3	147
85	The great balancing act: regulation and fate of antiviral T-cell interactions. <i>Immunological Reviews</i> , 2013, 255, 110-124.	2.8	19
87	Immune modulation by genetic modification of dendritic cells with lentiviral vectors. <i>Virus Research</i> , 2013, 176, 1-15.	1.1	20
88	Antigen Availability Determines CD8+ T Cell-Dendritic Cell Interaction Kinetics and Memory Fate Decisions. <i>Immunity</i> , 2013, 39, 496-507.	6.6	147
89	Turning Tumors into Vaccines: Co-opting the Innate Immune System. <i>Immunity</i> , 2013, 39, 27-37.	6.6	93
90	Immunotherapy for advanced melanoma: Fulfilling the promise. <i>Cancer Treatment Reviews</i> , 2013, 39, 879-885.	3.4	44
91	Exploiting Apoptosis for Therapeutic Tolerance Induction. <i>Journal of Immunology</i> , 2013, 191, 5341-5346.	0.4	73
92	Apoptotic cell administration enhances pancreatic islet engraftment by induction of regulatory T cells and tolerogenic dendritic cells. <i>Cellular and Molecular Immunology</i> , 2013, 10, 393-402.	4.8	26

#	ARTICLE	IF	CITATIONS
93	Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 1091-1100.	2.5	213
94	Imaging dynamics of CD11c ⁺ cells and Foxp3 ⁺ cells in progressive autoimmune insulinitis in the NOD mouse model of type 1 diabetes. <i>Diabetologia</i> , 2013, 56, 2669-2678.	2.9	37
95	CD4 ⁺ T cells modulate CD4 ⁺ T cell response via inhibition of IL-12 production by DCs. <i>European Journal of Immunology</i> , 2013, 43, 439-446.	1.6	4
96	Engineering antigens for in situ erythrocyte binding induces T-cell deletion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E60-8.	3.3	167
97	The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. <i>Nature Immunology</i> , 2013, 14, 152-161.	7.0	428
98	Notch signaling regulates PD-1 expression during CD8 ⁺ T cell activation. <i>Immunology and Cell Biology</i> , 2013, 91, 82-88.	1.0	105
99	Peripheral tolerance and autoimmunity: lessons from in vivo imaging. <i>Immunologic Research</i> , 2013, 55, 146-154.	1.3	8
100	The Transcription Factor NFAT Exhibits Signal Memory during Serial T Cell Interactions with Antigen-Presenting Cells. <i>Immunity</i> , 2013, 38, 237-249.	6.6	155
101	Building tolerance by dismantling synapses: inhibitory receptor signaling in natural killer cells. <i>Immunological Reviews</i> , 2013, 251, 143-153.	2.8	11
102	Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8 ⁺ T Cell-mediated Hepatic Antiviral Immunity. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e72.	2.3	48
103	The integration of T cell migration, differentiation and function. <i>Nature Reviews Immunology</i> , 2013, 13, 309-320.	10.6	504
104	IL-17RA Is Essential for Optimal Localization of Follicular Th Cells in the Germinal Center Light Zone To Promote Autoantibody-Producing B Cells. <i>Journal of Immunology</i> , 2013, 191, 1614-1624.	0.4	80
105	Effector T cell responses in non-lymphoid tissues: insights from in vivo imaging. <i>Immunology and Cell Biology</i> , 2013, 91, 290-296.	1.0	37
106	Actin cytoskeleton control of the comings and goings of T lymphocytes. <i>Tissue Antigens</i> , 2013, 82, 301-311.	1.0	14
107	PD-1, but Not PD-L1, Expressed by Islet-Reactive CD4 ⁺ T Cells Suppresses Infiltration of the Pancreas During Type 1 Diabetes. <i>Diabetes</i> , 2013, 62, 2859-2869.	0.3	64
108	Differentiated thyroid carcinomas and their B7H1 shield. <i>Future Oncology</i> , 2013, 9, 1417-1419.	1.1	13
109	Multistage T Cell-Dendritic Cell Interactions Control Optimal CD4 T Cell Activation through the ADAP-SKAP55 Signaling Module. <i>Journal of Immunology</i> , 2013, 191, 2372-2383.	0.4	17
110	Th2 Cell-Intrinsic Hypo-Responsiveness Determines Susceptibility to Helminth Infection. <i>PLoS Pathogens</i> , 2013, 9, e1003215.	2.1	54

#	ARTICLE	IF	CITATIONS
111	New perspectives in transplantation through intravital microscopy imaging. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 6-12.	0.8	22
112	PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. <i>Journal of Experimental Medicine</i> , 2013, 210, 757-774.	4.2	211
113	Dendritic Cell Subsets in Type 1 Diabetes: Friend or Foe?. <i>Frontiers in Immunology</i> , 2013, 4, 415.	2.2	43
114	Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-19.	3.3	12
115	Melanoma Mutagenesis and Aberrant Cell Signaling. <i>Cancer Control</i> , 2013, 20, 261-281.	0.7	29
116	Sinomenine inhibits the expression of PD-L1 in the peripheral blood mononuclear cells of mesangial proliferative nephritis patients. <i>Molecular Medicine Reports</i> , 2013, 7, 1223-1228.	1.1	11
117	Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression. <i>Oncology Letters</i> , 2013, 5, 1519-1526.	0.8	14
119	The nature of activatory and tolerogenic dendritic cell-derived signal II. <i>Frontiers in Immunology</i> , 2013, 4, 53.	2.2	91
120	Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors. <i>Brain Tumor Research and Treatment</i> , 2013, 1, 2.	0.4	15
121	Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 567.	1.0	206
122	Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 271.	1.8	38
123	Targeting Dendritic Cell Function during Systemic Autoimmunity to Restore Tolerance. <i>International Journal of Molecular Sciences</i> , 2014, 15, 16381-16417.	1.8	19
124	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
125	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. , 2014, , .		4
126	Antigen-specific therapy against Type 1 diabetes: mechanisms and perspectives. <i>Immunotherapy</i> , 2014, 6, 155-164.	1.0	13
127	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27297.	2.1	99
128	Real-time immune cell interactions in target tissue during autoimmune-induced damage and graft tolerance. <i>Journal of Experimental Medicine</i> , 2014, 211, 441-456.	4.2	56
129	Engineering better immunotherapies via RNA interference. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3165-3174.	1.4	19

#	ARTICLE	IF	CITATIONS
130	CD8+T Cell Activation Associated with Viral Replication in Chronic Infection. The Egyptian Journal of Hospital Medicine, 2014, 57, 395-402.	0.0	0
131	A Promoter Region Polymorphism in <i>PDCD-1</i> Gene Is Associated with Risk of Rheumatoid Arthritis in the Han Chinese Population of Southeastern China. International Journal of Genomics, 2014, 2014, 1-8.	0.8	29
132	Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation. Frontiers in Physiology, 2014, 5, 279.	1.3	61
133	The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection. Immunity, 2014, 41, 802-814.	6.6	294
134	Liver-primed CD8 ⁺ T cells suppress antiviral adaptive immunity through galectin-9-independent T cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology, 2014, 59, 1351-1365.	3.6	40
135	The Immunological Synapse. Cancer Immunology Research, 2014, 2, 1023-1033.	1.6	330
136	Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2014, 43, 101-108.	0.6	79
137	Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells. Cancer Journal (Sudbury, Mass), 2014, 20, 160-165.	1.0	35
138	B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis. Journal of Thoracic Oncology, 2014, 9, 1036-1040.	0.5	208
139	Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer. Cancer Journal (Sudbury, Mass), 2014, 20, 160-165.	1.0	35
140	IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. Future Oncology, 2014, 10, 937-948.	1.1	10
141	Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. Frontiers in Immunology, 2014, 5, 206.	2.2	108
142	Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes. PLoS ONE, 2014, 9, e89561.	1.1	54
143	Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy. Frontiers in Immunology, 2014, 5, 74.	2.2	39
144	Tfh Cell Differentiation and Their Function in Promoting B-Cell Responses. Advances in Experimental Medicine and Biology, 2014, 841, 153-180.	0.8	10
145	Host bone marrow-derived IL-12 enhances donor T cell engraftment in a mouse model of bone marrow transplantation. Journal of Hematology and Oncology, 2014, 7, 16.	6.9	6
146	Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility. Cancer Immunology Research, 2014, 2, 970-980.	1.6	68
147	New treatment strategies for HPV-positive head and neck cancer. European Archives of Oto-Rhino-Laryngology, 2014, 271, 1861-1867.	0.8	54

#	ARTICLE	IF	CITATIONS
148	Leukocyte migration in the interstitial space of non-lymphoid organs. <i>Nature Reviews Immunology</i> , 2014, 14, 232-246.	10.6	194
149	Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues. <i>Immunity</i> , 2014, 40, 235-247.	6.6	210
150	Visualizing how T cells collect activation signals in vivo. <i>Current Opinion in Immunology</i> , 2014, 26, 56-62.	2.4	65
151	Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. <i>Nature Immunology</i> , 2014, 15, 393-401.	7.0	219
152	How T Cells Lose Their Touch. <i>Immunity</i> , 2014, 40, 169-171.	6.6	0
153	The balance of intestinal Foxp3 ⁺ regulatory T cells and Th17 cells and its biological significance. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 353-362.	1.3	23
154	Follicular T _H 1 helper cells: controlled localization and cellular interactions. <i>Immunology and Cell Biology</i> , 2014, 92, 28-33.	1.0	24
155	The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2014, 7, 1-17.	0.6	83
156	Differential Kinetics of Antigen Dependency of CD4 ⁺ and CD8 ⁺ T Cells. <i>Journal of Immunology</i> , 2014, 192, 3507-3517.	0.4	42
157	Different subsets of natural killer T cells may vary in their roles in health and disease. <i>Immunology</i> , 2014, 142, 321-336.	2.0	87
158	Pathogen-Related Differences in the Abundance of Presented Antigen Are Reflected in CD4 ⁺ T Cell Dynamic Behavior and Effector Function in the Lung. <i>Journal of Immunology</i> , 2014, 192, 1651-1660.	0.4	22
159	T Helper Cell Differentiation and Their Function. <i>Advances in Experimental Medicine and Biology</i> , 2014, , .	0.8	7
160	Tumour-stroma crosstalk in the development of squamous cell carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 450-458.	1.2	39
161	The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity. <i>Journal of Immunology</i> , 2014, 193, 3835-3841.	0.4	178
162	Intestinal Macrophages and DCs Close the Gap on Tolerance. <i>Immunity</i> , 2014, 40, 171-173.	6.6	9
163	An evolving autoimmune microenvironment regulates the quality of effector T cell restimulation and function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9223-9228.	3.3	64
164	PD-1 deletion restores susceptibility to experimental autoimmune encephalomyelitis in miR-155-deficient mice. <i>International Immunology</i> , 2014, 26, 407-415.	1.8	17
165	Visualization and dynamic analysis of host-pathogen interactions. <i>Current Opinion in Immunology</i> , 2014, 29, 8-15.	2.4	14

#	ARTICLE	IF	CITATIONS
166	Tolerogenic dendritic cells: molecular and cellular mechanisms in transplantation. <i>Journal of Leukocyte Biology</i> , 2013, 95, 53-69.	1.5	37
167	Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: Interrogation by urinary cell mRNA profiling. <i>Transplantation Reviews</i> , 2014, 28, 145-154.	1.2	6
168	T cell migration in intact lymph nodes in vivo. <i>Current Opinion in Cell Biology</i> , 2014, 30, 17-24.	2.6	37
169	The PD-1/PD-Ls pathway and autoimmune diseases. <i>Cellular Immunology</i> , 2014, 290, 72-79.	1.4	298
170	Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. <i>Oncology Letters</i> , 2014, 8, 1461-1469.	0.8	46
172	Decreased Programmed Death-1 Expression on the T Cells of Patients With Ankylosing Spondylitis. <i>American Journal of the Medical Sciences</i> , 2015, 349, 488-492.	0.4	14
173	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. <i>Biomarkers in Cancer</i> , 2015, 7s2, BIC.S29325.	3.6	51
174	Pembrolizumab in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 315-325.	0.1	4
175	Immunotherapy for Advanced Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 383-391.	1.0	10
176	Emerging Role for Novel Immunotherapy Agents in Metastatic Renal Cell Carcinoma: From Bench to Bedside. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e291-e297.	1.8	4
177	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015, 3, 467-489.	2.1	38
178	Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?. <i>Frontiers in Immunology</i> , 2015, 6, 258.	2.2	16
179	Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 271.	2.2	36
180	Imaging of NKT Cell Recirculation and Tissue Migration during Antimicrobial Immunity. <i>Frontiers in Immunology</i> , 2015, 6, 356.	2.2	2
181	T Cell Motility as Modulator of Interactions with Dendritic Cells. <i>Frontiers in Immunology</i> , 2015, 6, 559.	2.2	7
182	T Lymphocyte Migration: An Action Movie Starring the Actin and Associated Actors. <i>Frontiers in Immunology</i> , 2015, 6, 586.	2.2	81
183	The Polyunsaturated Fatty Acids Arachidonic Acid and Docosahexaenoic Acid Induce Mouse Dendritic Cells Maturation but Reduce T-Cell Responses In Vitro. <i>PLoS ONE</i> , 2015, 10, e0143741.	1.1	41
184	Cancer and the Immune System: Basic Concepts and Targets for Intervention. <i>Seminars in Oncology</i> , 2015, 42, 523-538.	0.8	220

#	ARTICLE	IF	CITATIONS
185	Therapeutic Antibodies in Cancer Therapy. , 2015, , 95-120.		1
186	Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming. Nature Communications, 2015, 6, 6219.	5.8	107
187	T cell exhaustion during persistent viral infections. Virology, 2015, 479-480, 180-193.	1.1	251
188	Recent Insight into the Role of the <sc>PD</sc>â€1/<sc>PD</sc>â€L1 Pathway in Fetoâ€Maternal Tolerance and Pregnancy. American Journal of Reproductive Immunology, 2015, 74, 201-208.	1.2	58
189	Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects. Archives of Pharmacal Research, 2015, 38, 1415-1433.	2.7	14
190	Confusing signals: Recent progress in CTLA-4 biology. Trends in Immunology, 2015, 36, 63-70.	2.9	313
191	Cellular Energy Metabolism in T-Lymphocytes. International Reviews of Immunology, 2015, 34, 34-49.	1.5	21
192	Antigen Recognition in the Islets Changes with Progression of Autoimmune Islet Infiltration. Journal of Immunology, 2015, 194, 522-530.	0.4	56
194	Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncolmmunology, 2015, 4, e1008371.	2.1	227
195	CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells. Journal of Immunology, 2015, 195, 1054-1063.	0.4	34
196	The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where. , 2015, 154, 36-56.		128
197	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncolmmunology, 2015, 4, e1008814.	2.1	102
198	Synthetic Nanoparticles for Vaccines and Immunotherapy. Chemical Reviews, 2015, 115, 11109-11146.	23.0	623
199	Inflammation and Lung Cancer. , 2015, , .		2
200	Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. Frontiers in Immunology, 2015, 6, 127.	2.2	51
201	Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathway. Cancer Immunology, Immunotherapy, 2015, 64, 1383-1392.	2.0	32
202	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. , 2015, , 709-738.e8.		0
203	T Cells. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2050-2064.	2.2	59

#	ARTICLE	IF	CITATIONS
204	Lentiviral vectors in cancer immunotherapy. <i>Immunotherapy</i> , 2015, 7, 271-284.	1.0	28
205	Taming the TCR: Antigen-Specific Immunotherapeutic Agents for Autoimmune Diseases. <i>International Reviews of Immunology</i> , 2015, 34, 460-485.	1.5	8
206	Overcoming T cell exhaustion in infection and cancer. <i>Trends in Immunology</i> , 2015, 36, 265-276.	2.9	856
207	Cutting Edge: Identification of Autoreactive CD4+ and CD8+ T Cell Subsets Resistant to PD-1 Pathway Blockade. <i>Journal of Immunology</i> , 2015, 194, 3551-3555.	0.4	46
208	Î²-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection. <i>Gene Therapy</i> , 2015, 22, 430-438.	2.3	42
209	Anti-“PD-1 Therapy in Melanoma. <i>Seminars in Oncology</i> , 2015, 42, 466-473.	0.8	41
210	PD-L1-Driven Tolerance Protects Neurogenin3-Induced Islet Neogenesis to Reverse Established Type 1 Diabetes in NOD Mice. <i>Diabetes</i> , 2015, 64, 529-540.	0.3	21
211	Complement protein C1q bound to apoptotic cells suppresses human macrophage and dendritic cell-mediated Th17 and Th1 T cell subset proliferation. <i>Journal of Leukocyte Biology</i> , 2015, 97, 147-160.	1.5	92
212	T-bet regulates differentiation of forkhead box protein 3+regulatory T cells in programmed cell death-1-deficient mice. <i>Clinical and Experimental Immunology</i> , 2015, 179, 197-209.	1.1	5
213	Emerging immune checkpoints for cancer therapy. <i>Acta Oncologica</i> , 2015, 54, 1706-1713.	0.8	40
214	Breast cancer and immunology: biomarker and therapeutic developments. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1215-1222.	1.1	9
215	Cytotoxic T lymphocyte antigen 4 decreases humoral and cellular immunity by adenovirus to enhance target GFP gene transfer in C57BL/6 mice. <i>Immunopharmacology and Immunotoxicology</i> , 2015, 37, 520-526.	1.1	1
216	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 365-377.	0.9	103
217	Antigen-induced regulation of T cell motility, interaction with antigen-presenting cells and activation through endogenous thrombospondin-1 and its receptors. <i>Immunology</i> , 2015, 144, 687-703.	2.0	13
218	IL-10-overexpressing B cells regulate innate and adaptive immune responses. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 771-780.e8.	1.5	123
219	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5855-5866.	1.0	11
220	Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody. <i>International Journal of Nanomedicine</i> , 2016, 11, 955.	3.3	27
221	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives. <i>Translational Lung Cancer Research</i> , 2016, 5, 628-636.	1.3	15

#	ARTICLE	IF	CITATIONS
222	Effector T Lymphocyte Migration to and Within Non-Lymphoid Tissues. , 2016, , 493-504.		1
223	PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight, 2016, 1, .	2.3	128
224	Clinical utility of nivolumab in the treatment of advanced melanoma. Therapeutics and Clinical Risk Management, 2016, 12, 313.	0.9	16
225	Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition. Frontiers in Immunology, 2016, 7, 24.	2.2	44
226	A Perspective of Immunotherapy for Prostate Cancer. Cancers, 2016, 8, 64.	1.7	28
227	TLR3-Induced Maturation of Murine Dendritic Cells Regulates CTL Responses by Modulating PD-L1 Trafficking. PLoS ONE, 2016, 11, e0167057.	1.1	25
228	CTC immune escape mediated by PD-L1. Medical Hypotheses, 2016, 93, 138-139.	0.8	35
229	Immune Checkpoint Therapies in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 117-120.	1.0	46
230	Immunotherapy for breast cancer: past, present, and future. Cancer and Metastasis Reviews, 2016, 35, 525-546.	2.7	49
231	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
232	Therapeutic Antibodies in Cancer Therapy. Advances in Experimental Medicine and Biology, 2016, 917, 95-120.	0.8	36
233	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs, 2016, 76, 925-945.	4.9	123
234	Novel immunotherapies for the treatment of melanoma. Immunotherapy, 2016, 8, 613-632.	1.0	5
235	Malignant melanomaâ€”The cradle of anti-neoplastic immunotherapy. Critical Reviews in Oncology/Hematology, 2016, 106, 25-54.	2.0	33
236	Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity, 2016, 44, 1034-1051.	6.6	232
237	Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity, 2016, 44, 955-972.	6.6	462
238	Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity, 2016, 44, 924-938.	6.6	857
239	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 2016, 13, 473-486.	12.5	831

#	ARTICLE	IF	CITATIONS
240	Basic Rules of T Cell Migration. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 1-19.	0.1	3
241	Programmed Death 1 Expression on CD4 + T Cells Predicts Mortality after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2172-2179.	2.0	19
242	Varicella-Zoster Virus Downregulates Programmed Death Ligand 1 and Major Histocompatibility Complex Class I in Human Brain Vascular Adventitial Fibroblasts, Perineurial Cells, and Lung Fibroblasts. Journal of Virology, 2016, 90, 10527-10534.	1.5	21
243	PD-1/PD-L and autoimmunity: A growing relationship. Cellular Immunology, 2016, 310, 27-41.	1.4	211
244	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy, 2016, 8, 775-784.	1.0	24
245	Development of T follicular helper cells and their role in disease and immune system. Biomedicine and Pharmacotherapy, 2016, 84, 1668-1678.	2.5	46
246	Efficient generation of monoclonal antibodies against peptide in the context of MHCII using magnetic enrichment. Nature Communications, 2016, 7, 11804.	5.8	26
247	Immunomodulatory Functions of BTLA and HVEM Govern Induction of Extrathymic Regulatory T Cells and Tolerance by Dendritic Cells. Immunity, 2016, 45, 1066-1077.	6.6	124
248	Nivolumab in melanoma. Expert Review of Anticancer Therapy, 2016, 16, 1247-1261.	1.1	20
249	Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways. Scientific Reports, 2016, 6, 33869.	1.6	13
250	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. New England Journal of Medicine, 2016, 375, 1767-1778.	13.9	1,025
251	Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. , 2016, 4, 89.		81
252	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nature Reviews Urology, 2016, 13, 420-431.	1.9	78
253	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2016, 29, 832-845.	7.7	645
254	Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care, 2016, 11, 108-115.	0.8	45
255	Novel insights into cutaneous immune systems revealed by in vivo imaging. Allergology International, 2016, 65, 228-234.	1.4	7
256	Methotrexate and its therapeutic antagonists caffeine and theophylline, target a motogenic T cell mechanism driven by thrombospondin-1 (TSP-1). European Journal of Immunology, 2016, 46, 1279-1290.	1.6	10
257	T follicular regulatory cells. Immunological Reviews, 2016, 271, 246-259.	2.8	261

#	ARTICLE	IF	CITATIONS
258	The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Immunity</i> , 2016, 44, 143-154.	6.6	76
259	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 389-396.	1.4	35
260	Basics of PD-1 in self-tolerance, infection, and cancer immunity. <i>International Journal of Clinical Oncology</i> , 2016, 21, 448-455.	1.0	74
261	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016, 34, 539-573.	9.5	718
262	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 259-268.	3.2	30
263	T follicular helper cells, T follicular regulatory cells and autoimmunity. <i>International Immunology</i> , 2016, 28, 173-179.	1.8	89
264	Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. <i>Pediatric Research</i> , 2016, 79, 371-377.	1.1	12
265	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 58-71.	3.3	49
266	Intravital real-time analysis of T-cell activation in health and disease. <i>Cell Calcium</i> , 2017, 64, 118-129.	1.1	21
267	Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity. <i>Autoimmunity</i> , 2017, 50, 71-81.	1.2	55
268	Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 7.	1.3	46
269	Dendritic cells in host response to biologic scaffolds. <i>Seminars in Immunology</i> , 2017, 29, 41-48.	2.7	24
270	Anti-CD3 treatment upregulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity. <i>Immunology</i> , 2017, 151, 248-260.	2.0	29
271	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , 2017, 18, e143-e152.	5.1	1,612
272	PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load. <i>Scientific Reports</i> , 2017, 7, 43627.	1.6	52
273	Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 577-581.	0.9	33
274	PD-1 regulates KLRG1+ group 2 innate lymphoid cells. <i>Journal of Experimental Medicine</i> , 2017, 214, 1663-1678.	4.2	163
275	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. <i>Targeted Oncology</i> , 2017, 12, 301-308.	1.7	66

#	ARTICLE	IF	CITATIONS
276	Tâ€cell regulation through a basic suppressive mechanism targeting lowâ€density lipoprotein receptorâ€related protein 1. <i>Immunology</i> , 2017, 152, 308-327.	2.0	10
277	Relationship between CD4 Regulatory T Cells and Anergy In Vivo. <i>Journal of Immunology</i> , 2017, 198, 2527-2533.	0.4	73
278	Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma. <i>Cancer Immunology Research</i> , 2017, 5, 118-126.	1.6	56
279	Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms. <i>Cellular Immunology</i> , 2017, 322, 1-14.	1.4	114
280	Checkpoint immunotherapy in head and neck cancers. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 475-489.	2.7	33
281	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. <i>Cell Reports</i> , 2017, 20, 1818-1829.	2.9	220
282	Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. <i>Oncolmmunology</i> , 2017, 6, e1356146.	2.1	27
283	Dendritic Cells As Inducers of Peripheral Tolerance. <i>Trends in Immunology</i> , 2017, 38, 793-804.	2.9	157
284	Câ€C Chemokine Receptor Type 5 (CCR5)â€Mediated Docking of Transferred Tregs Protects Against Early Bloodâ€Brain Barrier Disruption After Stroke. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	65
285	Immune checkpoints in chronic obstructive pulmonary disease. <i>European Respiratory Review</i> , 2017, 26, 170045.	3.0	27
286	Unique B7-H1 expression on masticatory mucosae in the oral cavity and trans-coinhibition by B7-H1-expressing keratinocytes regulating CD4+ T cell-mediated mucosal tissue inflammation. <i>Mucosal Immunology</i> , 2017, 10, 650-660.	2.7	12
287	Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. <i>Bioengineered</i> , 2017, 8, 367-373.	1.4	7
288	New Approaches to Investigate Drug-Induced Hypersensitivity. <i>Chemical Research in Toxicology</i> , 2017, 30, 239-259.	1.7	18
289	Dendritic cells as gatekeepers of tolerance. <i>Seminars in Immunopathology</i> , 2017, 39, 153-163.	2.8	171
290	Regulatory T cells induced by B cells: a novel subpopulation of regulatory T cells. <i>Journal of Biomedical Science</i> , 2017, 24, 86.	2.6	64
292	Expression of soluble programmed death-1 protein in peripheral blood regulatory T cells and its effects on rheumatoid arthritis progression. <i>Molecular Medicine Reports</i> , 2017, 15, 460-466.	1.1	5
293	Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	8
294	T Regulatory Cells in Systemic Lupus Erythematosus: Current Knowledge and Future Prospects. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
295	Immune Regulation in Breast Cancer Metastasis and Immunotherapy. , 2017, , .		0
296	Programmed Cell Death-1/Programmed Death-ligand 1 Pathway. Chinese Medical Journal, 2017, 130, 986-992.	0.9	15
297	Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Frontiers in Pharmacology, 2017, 8, 382.	1.6	36
298	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. OncoTargets and Therapy, 2017, Volume 10, 2349-2363.	1.0	35
299	A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 2134.	1.8	55
300	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology, 2017, 8, 1597.	2.2	225
301	Peripherally Induced Regulatory T Cells: Recruited Protectors of the Central Nervous System against Autoimmune Neuroinflammation. Frontiers in Immunology, 2017, 8, 532.	2.2	42
302	Update on Dendritic Cell-Induced Immunological and Clinical Tolerance. Frontiers in Immunology, 2017, 8, 1514.	2.2	83
303	Are Follicular Regulatory T Cells Involved in Autoimmune Diseases?. Frontiers in Immunology, 2017, 8, 1790.	2.2	32
304	Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review. Journal of Immunology Research, 2017, 2017, 1-6.	0.9	45
305	Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug Design, Development and Therapy, 2017, Volume 11, 2851-2860.	2.0	34
306	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget, 2017, 8, 44960-44975.	0.8	82
307	PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders. Current Drug Delivery, 2017, 14, 791-796.	0.8	0
308	PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes. Oncotarget, 2017, 8, 51210-51223.	0.8	37
309	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. Translational Research, 2018, 196, 62-70.	2.2	9
310	PD-1 blocks lytic granule polarization with concomitant impairment of integrin outside-in signaling in the natural killer cell immunological synapse. Journal of Allergy and Clinical Immunology, 2018, 142, 1311-1321.e8.	1.5	13
311	Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4041-E4050.	3.3	564
312	Pigs expressing the human inhibitory ligand PD-L1 (CD274) provide a new source of xenogeneic cells and tissues with low immunogenic properties. Xenotransplantation, 2018, 25, e12387.	1.6	42

#	ARTICLE	IF	CITATIONS
313	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 47-53.	1.0	287
314	mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. <i>Molecular Therapy</i> , 2018, 26, 420-434.	3.7	132
315	SIRT1 and HIF1 α signaling in metabolism and immune responses. <i>Cancer Letters</i> , 2018, 418, 20-26.	3.2	107
316	Intravital mucosal imaging of CD8+ resident memory T cells shows tissue-autonomous recall responses that amplify secondary memory. <i>Nature Immunology</i> , 2018, 19, 173-182.	7.0	220
317	Inhibitors of the PD-1 Pathway in Tumor Therapy. <i>Journal of Immunology</i> , 2018, 200, 375-383.	0.4	112
318	Termination of T cell priming relies on a phase of unresponsiveness promoting disengagement from APCs and T cell division. <i>Journal of Experimental Medicine</i> , 2018, 215, 1481-1492.	4.2	21
319	The involvement of plasmacytoid cells in HIV infection and pathogenesis. <i>Cytokine and Growth Factor Reviews</i> , 2018, 40, 77-89.	3.2	14
320	Nivolumab in squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 409-420.	1.1	9
321	PD-1 and cancer: molecular mechanisms and polymorphisms. <i>Immunogenetics</i> , 2018, 70, 73-86.	1.2	100
322	PD-1 expression on CD8+ T cells regulates their differentiation within lung allografts and is critical for tolerance induction. <i>American Journal of Transplantation</i> , 2018, 18, 216-225.	2.6	23
323	The diverse functions of the PD1 inhibitory pathway. <i>Nature Reviews Immunology</i> , 2018, 18, 153-167.	10.6	1,210
324	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. <i>European Journal of Cancer</i> , 2018, 88, 38-47.	1.3	248
325	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	1.1	57
326	Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells. <i>Critical Reviews in Immunology</i> , 2018, 38, 379-401.	1.0	58
327	Differential Impact of T-bet and IFN γ on Pancreatic Islet Allograft Rejection. <i>Transplantation</i> , 2018, 102, 1496-1504.	0.5	7
328	CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 2737.	2.2	123
329	Elevated expression of IL-17RB and ST2 on myeloid dendritic cells is associated with a Th2-skewed eosinophilic inflammation in nasal polyps. <i>Clinical and Translational Allergy</i> , 2018, 8, 50.	1.4	6
330	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	3.6	121

#	ARTICLE	IF	CITATIONS
331	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. <i>Genome Medicine</i> , 2018, 10, 79.	3.6	36
332	MGCD0103 induces apoptosis and simultaneously increases the expression of NF- κ B and PD-L1 in classical Hodgkin's lymphoma. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 3827-3834.	0.8	4
333	Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1061-1071.	1.4	27
334	Targeting IKK β in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKK β Inhibitors. <i>Cells</i> , 2018, 7, 115.	1.8	91
335	Interferon-gamma drives programmed death-ligand 1 expression on islet β cells to limit T cell function during autoimmune diabetes. <i>Scientific Reports</i> , 2018, 8, 8295.	1.6	100
336	Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-7.	0.8	16
337	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. <i>Oncotarget</i> , 2018, 7, e1466018.	2.1	51
338	The Immune Response to Glioblastoma: Overview and Focus on Checkpoint Blockade. , 2018, , 653-668.		0
339	Au-CGKRK Nanoconjugates for Combating Cancer through T-Cell-Driven Therapeutic RNA Interference. <i>ACS Omega</i> , 2018, 3, 8663-8676.	1.6	20
340	Mechanisms of Tolerance Induction by Dendritic Cells In Vivo. <i>Frontiers in Immunology</i> , 2018, 9, 350.	2.2	155
341	Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune Diabetes. <i>Frontiers in Immunology</i> , 2018, 9, 1006.	2.2	8
342	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. <i>Biomedicines</i> , 2018, 6, 26.	1.4	16
343	Polymer nanoparticles as adjuvants in cancer immunotherapy. <i>Nano Research</i> , 2018, 11, 5769-5786.	5.8	66
344	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. <i>Future Oncology</i> , 2018, 14, 41-60.	1.1	12
345	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018, 67, 2056-2067.	6.1	179
346	Cancer as a Systemic Disease That Requires a Systemic Approach. , 2018, , 79-90.		2
347	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. <i>Cancer Treatment Reviews</i> , 2019, 74, 49-60.	3.4	38
348	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , 2019, 52, 144-160.	1.2	10

#	ARTICLE	IF	CITATIONS
349	Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes. <i>Journal of Immunology</i> , 2019, 203, 844-852.	0.4	15
350	A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). <i>Oncologist</i> , 2019, 24, 1439-1445.	1.9	40
351	Combined Application of Nivolumab and Intravesical Bacillus Calmette-Guérin Led to Acute-Onset Type 1 Diabetes. <i>Case Reports in Oncology</i> , 2019, 12, 430-433.	0.3	2
352	Advanced urothelial cancer: a radiology update. <i>Abdominal Radiology</i> , 2019, 44, 3858-3873.	1.0	5
353	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. <i>Cancers</i> , 2019, 11, 872.	1.7	50
354	A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1066.	1.3	43
355	Immune-Inflammatory Responses in Atherosclerosis: The Role of Myeloid Cells. <i>Journal of Clinical Medicine</i> , 2019, 8, 1798.	1.0	45
356	PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. , 2019, 7, 228.		26
357	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4263.	1.8	17
358	Effects of gold nanoprisim-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer. <i>Acta Biomaterialia</i> , 2019, 99, 307-319.	4.1	63
359	Complex interactions between the microbiome and cancer immune therapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 567-585.	2.7	28
360	Î² cell responses to inflammation. <i>Molecular Metabolism</i> , 2019, 27, S104-S113.	3.0	11
361	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	1.0	41
362	Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses. <i>Molecular Therapy</i> , 2019, 27, 1892-1905.	3.7	28
363	Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2836.	1.8	23
364	Solid Tumors Challenges and New Insights of CAR T Cell Engineering. <i>Stem Cell Reviews and Reports</i> , 2019, 15, 619-636.	1.7	71
365	Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy. <i>Theranostics</i> , 2019, 9, 2299-2314.	4.6	88
366	Development of immune checkpoint therapy for cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 1244-1254.	4.2	125

#	ARTICLE	IF	CITATIONS
367	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. <i>Frontiers of Medicine</i> , 2019, 13, 438-450.	1.5	32
368	Depletion of PD-1-positive cells ameliorates autoimmune disease. <i>Nature Biomedical Engineering</i> , 2019, 3, 292-305.	11.6	48
369	Bacillus Calmette-Guérin Induces PD-L1 Expression on Antigen-Presenting Cells via Autocrine and Paracrine Interleukin-STAT3 Circuits. <i>Scientific Reports</i> , 2019, 9, 3655.	1.6	19
370	Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor. <i>International Journal of Cancer</i> , 2019, 145, 1660-1668.	2.3	65
371	Interstitial Migration of CD8 ⁺ T Cells in the Small Intestine Is Dynamic and Is Dictated by Environmental Cues. <i>Cell Reports</i> , 2019, 26, 2859-2867.e4.	2.9	19
372	Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions. <i>Frontiers in Immunology</i> , 2019, 10, 4.	2.2	11
373	Changes in plasma EBV-DNA and immune status in patients with nasopharyngeal carcinoma after treatment with intensity-modulated radiotherapy. <i>Diagnostic Pathology</i> , 2019, 14, 23.	0.9	8
374	T cell and dendritic cell interactions in lymphoid organs: More than just being in the right place at the right time. <i>Immunological Reviews</i> , 2019, 289, 115-128.	2.8	15
375	Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. <i>Abdominal Radiology</i> , 2019, 44, 1917-1927.	1.0	37
376	Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 176.	1.7	18
377	Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 236.	1.0	49
378	Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy. <i>Archives of Pharmacal Research</i> , 2019, 42, 150-158.	2.7	28
379	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	1.6	106
380	Silencing PD-1 and PD-L1: the potential of PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells. <i>Immunotherapy</i> , 2019, 11, 369-372.	1.0	9
381	Meglumine acridone acetate, the ionic salt of CMA and N-methylglucamine, induces apoptosis in human PBMCs via the mitochondrial pathway. <i>Scientific Reports</i> , 2019, 9, 18240.	1.6	6
382	PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients. <i>Medicine (United States)</i> , 2019, 98, e17608.	0.4	20
383	Obstacles to T cell migration in the tumor microenvironment. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2019, 63, 22-30.	0.7	30
384	Class II MHC antigen processing in immune tolerance and inflammation. <i>Immunogenetics</i> , 2019, 71, 171-187.	1.2	77

#	ARTICLE	IF	CITATIONS
385	Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration. <i>Pathology and Oncology Research</i> , 2019, 25, 1437-1443.	0.9	8
386	Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance. <i>Annals of the New York Academy of Sciences</i> , 2020, 1461, 73-103.	1.8	15
387	<i>Cancer Immunology.</i> , 2020, , 84-96.e5.		0
388	Histologic patterns of liver injury induced by anti-PD-1 therapy. <i>Gastroenterology Report</i> , 2020, 8, 50-55.	0.6	24
389	Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. <i>European Urology Oncology</i> , 2020, 3, 680-686.	2.6	14
390	Immunity, Hypoxia, and Metabolism—the Triad of Cancer: Implications for Immunotherapy. <i>Physiological Reviews</i> , 2020, 100, 1-102.	13.1	190
391	Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. <i>Regenerative Engineering and Translational Medicine</i> , 2020, 6, 29-49.	1.6	16
392	PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells. <i>American Journal of Surgical Pathology</i> , 2020, 44, 174-181.	2.1	52
393	Challenges in assessing solid tumor responses to immunotherapy. <i>Cancer Gene Therapy</i> , 2020, 27, 528-538.	2.2	36
394	Advances of immune checkpoints in colorectal cancer treatment. <i>Biomedicine and Pharmacotherapy</i> , 2020, 123, 109745.	2.5	21
395	Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. <i>International Immunopharmacology</i> , 2020, 79, 106088.	1.7	39
396	Cellular Signaling Pathways in Medium and Large Vessel Vasculitis. <i>Frontiers in Immunology</i> , 2020, 11, 587089.	2.2	40
397	Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 589641.	2.2	21
398	Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 3021-3034.	1.1	3
399	Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors. <i>Medicine (United States)</i> , 2020, 99, e21273.	0.4	9
400	Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 230.	0.4	9
401	Overcoming Immune Evasion in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8984.	1.8	88
402	<p>Which idea is better with regard to immune response? Opioid anesthesia or opioid free anesthesia</p>. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 859-869.	1.6	14

#	ARTICLE	IF	CITATIONS
403	PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment. <i>Frontiers in Immunology</i> , 2020, 11, 590568.	2.2	9
404	PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity. <i>Nature Communications</i> , 2020, 11, 3998.	5.8	101
405	MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 540.	1.8	34
406	Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity. <i>Journal of Immunology</i> , 2020, 205, 1449-1460.	0.4	20
407	Evaluation of the role of B7-H3 haplotype in association with impaired B7-H3 expression and protection against type 1 diabetes in Chinese Han population. <i>BMC Endocrine Disorders</i> , 2020, 20, 123.	0.9	1
408	Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions. <i>Journal of Biological Chemistry</i> , 2020, 295, 18036-18050.	1.6	16
409	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1147-1158.	1.3	8
410	Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies. <i>Cancers</i> , 2020, 12, 2476.	1.7	39
411	Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. <i>Journal of the American Chemical Society</i> , 2020, 142, 18874-18885.	6.6	16
412	PD-1 suppresses the maintenance of cell couples between cytotoxic T cells and target tumor cells within the tumor. <i>Science Signaling</i> , 2020, 13, .	1.6	15
413	Hepatocellular Carcinoma—The Influence of Immunoanatomy and the Role of Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6757.	1.8	9
414	Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2020, 11, 569.	1.5	39
415	Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies. <i>Nature Reviews Endocrinology</i> , 2020, 16, 629-641.	4.3	49
416	Four Immune-Related Long Non-coding RNAs for Prognosis Prediction in Patients With Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 566491.	1.6	16
417	Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 1054.	2.0	77
418	Update on Hodgkin lymphoma from a radiologist's perspective. <i>Clinical Imaging</i> , 2020, 65, 65-77.	0.8	3
419	Dextran Sulfate Protects Pancreatic β -Cells, Reduces Autoimmunity, and Ameliorates Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, 1692-1707.	0.3	10
420	Immunotherapy for platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 484-488.	0.6	40

#	ARTICLE	IF	CITATIONS
421	Interleukin-17 promotes nitric oxide-dependent expression of PD-L1 in mesenchymal stem cells. <i>Cell and Bioscience</i> , 2020, 10, 73.	2.1	21
422	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 364.	2.2	50
423	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. <i>Frontiers in Medicine</i> , 2020, 7, 50.	1.2	11
424	High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 914.	1.3	45
425	Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. <i>Clinical and Experimental Immunology</i> , 2020, 200, 131-140.	1.1	104
426	PD-1 and PD-L1 expression on T cell subsets in women with unexplained recurrent pregnancy losses. <i>American Journal of Reproductive Immunology</i> , 2020, 83, e13230.	1.2	23
427	Germline Features Associated with Immune Infiltration in Solid Tumors. <i>Cell Reports</i> , 2020, 30, 2900-2908.e4.	2.9	35
428	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	1.8	21
429	Neoadjuvant checkpoint blockade for cancer immunotherapy. <i>Science</i> , 2020, 367, .	6.0	553
430	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. <i>Journal of Clinical Medicine</i> , 2020, 9, 286.	1.0	50
431	CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions. <i>FEBS Open Bio</i> , 2020, 10, 1162-1170.	1.0	3
432	Glioblastoma hijacks microglial gene expression to support tumor growth. <i>Journal of Neuroinflammation</i> , 2020, 17, 120.	3.1	71
433	Immunological aspects of nanocellulose. <i>Immunology Letters</i> , 2020, 222, 80-89.	1.1	50
434	Factors that influence the thymic selection of CD8 ⁺ intraepithelial lymphocytes. <i>Mucosal Immunology</i> , 2021, 14, 68-79.	2.7	13
435	Human microbiome and prostate cancer development: current insights into the prevention and treatment. <i>Frontiers of Medicine</i> , 2021, 15, 11-32.	1.5	17
436	The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1771-1776.	2.0	8
437	Immune checkpoint inhibitors and diabetes: Mechanisms and predictors. <i>Diabetes and Metabolism</i> , 2021, 47, 101193.	1.4	9
438	Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status. <i>Pathology</i> , 2021, 53, 462-469.	0.3	11

#	ARTICLE	IF	CITATIONS
439	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103160.	2.0	26
440	Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer. <i>Nano Today</i> , 2021, 36, 101025.	6.2	45
441	Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. <i>Onc Immunology</i> , 2021, 10, 1838140.	2.1	22
442	Autoimmune Polyglandular Syndromes. , 2021, , 884-903.		0
443	Programmed Death Ligand 1-Expressing Classical Dendritic Cells Mitigate -Induced Gastritis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 715-739.	2.3	9
444	PD-1 blockade exacerbates <i>Mycobacterium tuberculosis</i> infection in rhesus macaques. <i>Science Immunology</i> , 2021, 6, .	5.6	70
445	The PD-1:PD-L1 axis in Inflammatory Arthritis. <i>BMC Rheumatology</i> , 2021, 5, 1.	0.6	29
446	Co-Inhibitors of Second Signal of Lymphocyte Response in Human Renal Transplants: PD-L2, GITR, and ILT-2/3/5 Positive Cells from Aspiration Biopsies Associate with Acute Rejection-Freedom. <i>Open Journal of Nephrology</i> , 2021, 11, 58-77.	0.0	0
447	A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma. <i>Bioengineered</i> , 2021, 12, 1642-1662.	1.4	6
448	Effects of programmed death ligand 1 on the prognosis of neuroblastoma. <i>Medicine (United States)</i> , 2021, 100, e24920.	0.4	0
449	Unraveling the Role of Immune Checkpoints in Leishmaniasis. <i>Frontiers in Immunology</i> , 2021, 12, 620144.	2.2	18
450	Complement in Tumourigenesis and the Response to Cancer Therapy. <i>Cancers</i> , 2021, 13, 1209.	1.7	18
451	Regulatory T Cells in the Mosaic of Liver Transplantation Tolerance. , 0, , .		0
452	Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1882-1896.	1.4	10
453	Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. <i>Cancer Cell International</i> , 2021, 21, 239.	1.8	35
454	Checkpoint Inhibitor-Induced Colitisâ€”A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. <i>Pharmaceuticals</i> , 2021, 14, 367.	1.7	13
455	PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype. <i>PLoS Biology</i> , 2021, 19, e3001199.	2.6	32
456	Hypoxia-inducible factorâ€1 drives divergent immunomodulatory functions in the pathogenesis of autoimmune diseases. <i>Immunology</i> , 2021, 164, 31-42.	2.0	20

#	ARTICLE	IF	CITATIONS
457	The abscopal effect: a sense of DNA damage is in the air. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	19
459	Emerging concepts in PD-1 checkpoint biology. <i>Seminars in Immunology</i> , 2021, 52, 101480.	2.7	84
460	The Role of Programmed Death-1 in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 20.	1.7	11
461	Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1083-1097.	5.7	23
462	PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition. <i>Nature Communications</i> , 2021, 12, 2746.	5.8	41
463	Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy. <i>European Journal of Immunology</i> , 2021, 51, 1911-1920.	1.6	31
464	Actin Dynamics at the T Cell Synapse as Revealed by Immune-Related Actinopathies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 665519.	1.8	26
465	Strength and Numbers: The Role of Affinity and Avidity in the "Quality" of T Cell Tolerance. <i>Cells</i> , 2021, 10, 1530.	1.8	3
466	Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. <i>Cell</i> , 2021, 184, 3998-4015.e19.	13.5	92
467	Targeted delivery of regulatory macrophages to lymph nodes interferes with T cell priming by preventing the formation of stable immune synapses. <i>Cell Reports</i> , 2021, 35, 109273.	2.9	4
468	Metabolic Screening of Cytotoxic T-cell Effector Function Reveals the Role of CRAC Channels in Regulating Lethal Hit Delivery. <i>Cancer Immunology Research</i> , 2021, 9, 926-938.	1.6	5
469	Inflammation Determines the Capacity of Allogenic Endothelial Cells to Regulate Human Treg Expansion. <i>Frontiers in Immunology</i> , 2021, 12, 666531.	2.2	14
470	The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury. <i>Cell Communication and Signaling</i> , 2021, 19, 76.	2.7	14
471	Contributions of PD-L1 reverse signaling to dendritic cell trafficking. <i>FEBS Journal</i> , 2021, , .	2.2	3
472	Enhanced CD4+ and CD8+ T cell infiltrate within convex hull defined pancreatic islet borders as autoimmune diabetes progresses. <i>Scientific Reports</i> , 2021, 11, 17142.	1.6	7
473	The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models. <i>Cancer Management and Research</i> , 2021, Volume 13, 6045-6053.	0.9	8
474	An Engineered Patient-Derived Tumor Organoid Model That Can Be Disassembled to Study Cellular Responses in a Graded 3D Microenvironment. <i>Advanced Functional Materials</i> , 2021, 31, 2105349.	7.8	15
475	Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. <i>Cell Reports</i> , 2021, 36, 109538.	2.9	41

#	ARTICLE	IF	CITATIONS
476	MERTK on mononuclear phagocytes regulates T cell antigen recognition at autoimmune and tumor sites. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	15
477	CML derived exosomes promote tumor favorable functional performance in T cells. <i>BMC Cancer</i> , 2021, 21, 1002.	1.1	14
478	Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases. <i>Journal of Autoimmunity</i> , 2021, 123, 102702.	3.0	16
479	Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade. <i>Cancers</i> , 2021, 13, 4616.	1.7	13
480	Intravital imaging of interactions between iNKT and kupffer cells to clear free lipids during steatohepatitis. <i>Theranostics</i> , 2021, 11, 2149-2169.	4.6	9
481	Hyperprogression: A novel response pattern under immunotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e167.	1.7	22
482	Unleashing the Therapeutic Potential of Dendritic and T Cell Therapies Using RNA Interference. <i>Methods in Molecular Biology</i> , 2020, 2115, 259-280.	0.4	3
483	Organ Transplantation: Modulation of T-Cell Activation Pathways Initiated by Cell Surface Receptors to Suppress Graft Rejection. <i>Methods in Molecular Biology</i> , 2010, 677, 419-430.	0.4	2
484	The Effects of Somatostatin on Immune Cells, Functions and Diseases. , 2012, , 203-225.		1
485	Co-signal Molecules in T-Cell Activation. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 3-23.	0.8	45
486	The CD28â€“B7 Family of Co-signaling Molecules. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 25-51.	0.8	41
487	Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 85-133.	0.8	14
488	Cancer Immunology. , 2014, , 78-97.e5.		3
489	Expression of checkpoint molecules on myeloid-derived suppressor cells. <i>Immunology Letters</i> , 2017, 192, 1-6.	1.1	82
490	TAM kinase inhibition and immune checkpoint blockadeâ€“ a winning combination in cancer treatment?. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 141-151.	1.5	17
491	Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 501-510.	1.1	10
492	Imbalance of immunological synapse-kinapse states reflects tumor escape to immunity in glioblastoma. <i>JCI Insight</i> , 2018, 3, .	2.3	18
493	Suppressing T cell motility induced by antiâ€“CTLA-4 monotherapy improves antitumor effects. <i>Journal of Clinical Investigation</i> , 2012, 122, 3718-3730.	3.9	167

#	ARTICLE	IF	CITATIONS
494	Treatment of Type II Collagen-Induced Rat Rheumatoid Arthritis Model by Interleukin 10 (IL10)-Mesenchymal Stem Cells (BMSCs). <i>Medical Science Monitor</i> , 2019, 25, 2923-2934.	0.5	17
495	Basal LAT-diacylglycerol-RasGRP1 Signals in T Cells Maintain TCR β Gene Expression. <i>PLoS ONE</i> , 2011, 6, e25540.	1.1	24
496	Targeting CD28, CTLA-4 and PD-L1 Costimulation Differentially Controls Immune Synapses and Function of Human Regulatory and Conventional T-Cells. <i>PLoS ONE</i> , 2013, 8, e83139.	1.1	57
497	Programmed cell death-1, PD-1, is dysregulated in T cells from children with new onset type 1 diabetes. <i>PLoS ONE</i> , 2017, 12, e0183887.	1.1	31
498	PD-1 pathway-mediated regulation of islet-specific CD4+ T cell subsets in autoimmune diabetes. <i>Immunoendocrinology (Houston, Tex)</i> , 2016, 3, .	1.0	14
499	Differential expression of the costimulatory molecules CD86, CD28, CD152 and PD-1 correlates with the host-parasite outcome in leprosy. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2012, 107, 167-173.	0.8	15
500	New landscapes and horizons in hepatocellular carcinoma therapy. <i>Aging</i> , 2020, 12, 3053-3094.	1.4	37
501	<i>Cblb</i> -deficient T cells are less susceptible to PD-L1-mediated inhibition. <i>Oncotarget</i> , 2017, 8, 41841-41853.	0.8	19
502	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	0.8	29
503	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. <i>Oncotarget</i> , 2015, 6, 19393-19404.	0.8	61
504	The Nexus of Stem Cell-Derived Beta-Cells and Genome Engineering. <i>Review of Diabetic Studies</i> , 2017, 14, 39-50.	0.5	9
505	Melanoma immunotherapy dominates the field. <i>Annals of Translational Medicine</i> , 2016, 4, 269-269.	0.7	19
506	Dendritic Cells: A Double-Edge Sword in Atherosclerotic Inflammation. <i>Current Pharmaceutical Design</i> , 2015, 21, 1118-1123.	0.9	7
507	Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2012, 12, 224-235.	0.5	45
508	Immunoterapia z uÅ¼yciem przeciwciaÅ, monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. <i>Acta Haematologica Polonica</i> , 2018, 49, 207-227.	0.1	5
509	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 9-22.	0.1	10
510	Potential immunotherapy for Alzheimer disease and age-related dementia. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 21-25.	1.8	18
512	Signaling Mechanisms that Balance Anti-viral, Auto-reactive, and Antitumor Potential of Low Affinity T Cells. <i>Journal of Clinical & Cellular Immunology</i> , 2013, 01, .	1.5	29

#	ARTICLE	IF	CITATIONS
513	Immunotherapy in Cancer Treatment. Open Journal of Medical Microbiology, 2014, 04, 178-191.	0.1	5
514	TGF β ² -dependent expression of PD-1 and PD-L1 controls CD8 ⁺ T cell anergy in transplant tolerance. ELife, 2016, 5, e08133.	2.8	105
515	Response Assessment to Cancer Therapy. UNIPA Springer Series, 2021, , 249-257.	0.1	0
516	Developing Cancer Immunotherapies by the manipulation of Immune Checkpoints. IOSR Journal of Pharmacy, 2012, 2, 01-08.	0.1	0
517	Employing T Cell Homeostasis as an Antitumor Strategy. , 2014, , 83-105.		0
518	Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy. , 2015, , 191-209.		0
519	Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. Giornale Di Chirurgia, 2017, 37, 225-235.	0.5	6
520	Regulation of Anti-tumor T Cell Migration and Function: Contribution of Real-Time Imaging. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 21-49.	0.1	0
521	The Multifaceted Role of PD-1 in Health and Disease. , 2016, , 441-457.		0
523	Immune Checkpoint Inhibitors in the Treatment of Lymphomas. Klinicheskaya Onkologematologiya/Clinical Oncohematology, 2018, 11, 303-312.	0.1	10
528	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10 \rightarrow IL-10R Pathways in Acute Myeloid Leukemia. Pharmaceuticals, 2021, 14, 1105.	1.7	6
529	PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma. Indian Journal of Cancer, 2020, .	0.2	1
530	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
531	The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Science Immunology, 2021, 6, eabf4034.	5.6	22
533	mKLRL1 regulates the maturation of dendritic cells and plays important roles in immune tolerance. American Journal of Translational Research (discontinued), 2019, 11, 300-313.	0.0	0
535	Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110562.	0.6	5
536	Moving beyond velocity: Opportunities and challenges to quantify immune cell behavior*. Immunological Reviews, 2022, 306, 123-136.	2.8	7
537	Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2021, 25, 987-1005.	1.5	8

#	ARTICLE	IF	CITATIONS
538	Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms. <i>JCI Insight</i> , 2021, 6, .	2.3	11
539	Autoimmunity in motion: Mechanisms of immune regulation and destruction revealed by in vivo imaging*. <i>Immunological Reviews</i> , 2022, 306, 181-199.	2.8	0
540	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 810388.	2.2	9
542	Variegated Outcomes of T Cell Activation by Dendritic Cells in the Steady State. <i>Journal of Immunology</i> , 2022, 208, 539-547.	0.4	8
543	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. <i>Frontiers in Immunology</i> , 2021, 12, 806043.	2.2	7
544	The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	2
545	Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases. <i>Cancers</i> , 2022, 14, 792.	1.7	8
546	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. <i>Cell</i> , 2021, 184, 6262-6280.e26.	13.5	125
547	Effects of PD-1 Signaling on Immunometabolic Reprogramming. <i>Immunometabolism</i> , 2022, 4, .	0.7	10
549	Teaching cancer imaging in the era of precision medicine: Looking at the big picture. <i>European Journal of Radiology Open</i> , 2022, 9, 100414.	0.7	3
550	Immune-related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia. <i>Cancer Medicine</i> , 2022, 11, 3364-3380.	1.3	3
551	The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings. <i>Frontiers in Immunology</i> , 2022, 13, 773946.	2.2	9
552	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2022, 22, 40-50.	0.3	0
553	Immune Checkpoint Receptors Signaling in T Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3529.	1.8	12
554	PD-1 Targeted Nanoparticles Inhibit Activated T Cells and Alleviate Autoimmunity via Suppression of Cellular Energy Metabolism Mediated by PKM2. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 1711-1724.	3.3	5
555	PD-L1â€PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection. <i>Nature Immunology</i> , 2022, 23, 743-756.	7.0	47
556	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. <i>Nature Communications</i> , 2022, 13, 2176.	5.8	18
588	Immunotherapy-induced Colitis. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.1	5

#	ARTICLE	IF	CITATIONS
590	Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy. <i>ACS Central Science</i> , 2022, 8, 603-614.	5.3	24
591	The genetic influence of PD-1/PD-L1 axis single nucleotide polymorphisms on the incidence of type 1 diabetes mellitus in pediatric Egyptian patients. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	1
592	Cancer-Associated Fibroblasts and Squamous Epithelial Cells Constitute a Unique Microenvironment in a Mouse Model of Inflammation-Induced Colon Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	6
593	Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
594	PD-1/PD-L Axis in Neuroinflammation: New Insights. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	16
595	Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?. <i>Cells</i> , 2022, 11, 1854.	1.8	7
596	Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia. <i>Hematology</i> , 2022, 27, 659-671.	0.7	4
597	Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumor efficacy against castration-resistant prostate cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	18
598	The Role of Immune Checkpoints in Cancer Progression. , 0, , .		0
599	Proinflammatory signaling in islet β^2 cells propagates invasion of pathogenic immune cells in autoimmune diabetes. <i>Cell Reports</i> , 2022, 39, 111011.	2.9	11
600	Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
601	Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells. <i>Journal of Controlled Release</i> , 2022, 349, 425-433.	4.8	2
602	Lentivirus-mediated PD-L1 overexpression in bone marrow-derived dendritic cells induces immune tolerance in a rat keratoplasty model. <i>Transplant Immunology</i> , 2022, 74, 101654.	0.6	0
603	The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
604	Highly Sensitive Detection of the Immune Checkpoint PD-L1-Positive Circulating Tumor Cells Based on Steric Hindrance. <i>Analytical Chemistry</i> , 2022, 94, 11767-11772.	3.2	7
606	Computational design of PD-L1 small molecule inhibitors for cancer therapy. <i>Molecular Diversity</i> , 2023, 27, 1633-1644.	2.1	7
607	PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. <i>Clinics and Practice</i> , 2022, 12, 653-671.	0.6	8
608	Engineered T cell extracellular vesicles displaying PD-1 boost anti-tumor immunity. <i>Nano Today</i> , 2022, 46, 101606.	6.2	23

#	ARTICLE	IF	CITATIONS
609	PD-L1 enhances migration and invasion of trophoblasts by upregulating ARHGDI B via transcription factor PU.1. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	4
611	Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
612	B cell-T cell interplay in immune regulation: A focus on follicular regulatory T and regulatory B cell functions. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
613	A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
614	Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 4677-4696.	3.3	9
615	CXCR5+CD8 T cells: Potential immunotherapy targets or drivers of immune-mediated adverse events?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
616	Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
618	Qualitative analysis and numerical simulations of new model describing cancer. <i>Journal of Computational and Applied Mathematics</i> , 2023, 422, 114899.	1.1	12
619	Research progress on the intrinsic non-immune function of PD-L1 in tumors (Review). <i>Oncology Letters</i> , 2022, 25, .	0.8	3
620	Immunopathogenesis of Hepatitis B Virus Infection and Related Complications. <i>European Medical Journal Hepatology</i> , 0, , 84-92.	1.0	1
621	Human stem cell derived beta-like cells engineered to present PD-L1 improve transplant survival in NOD mice carrying human HLA class I. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
622	<i>Mycobacterium avium</i> subsp. paratuberculosis antigens induce cellular immune responses in cattle without causing reactivity to tuberculin in the tuberculosis skin test. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
623	Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer. <i>Genes and Diseases</i> , 2024, 11, 218-233.	1.5	6
624	Effect of the method of anesthetic aid on cellular immunity in periprosthetic infection of the hip joint: a prospective open randomized study. <i>Regional Anesthesia and Acute Pain Management</i> , 2023, 16, 195-204.	0.1	0
626	Immunomodulation under the lens of real-time in vivo imaging. <i>European Journal of Immunology</i> , 0, , .	1.6	0
627	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	1.7	8
628	The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114436.	2.5	2
629	Checkpoint Blockade in Hematologic Malignancies. , 2022, , 1-42.		0

#	ARTICLE	IF	CITATIONS
630	New Fractional Cancer Mathematical Model via IL-10 Cytokine and Anti-PD-L1 Inhibitor. <i>Fractal and Fractional</i> , 2023, 7, 151.	1.6	5
631	Knockdown of programmed death 1 inhibited progression of papillary thyroid carcinoma in mice. <i>Protein and Peptide Letters</i> , 2023, 30, .	0.4	0
632	Battling Non-Small Cell Lung Carcinoma: Applying Biomarkers Testing to Pick the Best Immune Checkpoint Inhibitors Therapy. , 0, 36, 36-43.		0
633	Immunotherapeutic and their immunological aspects: Current treatment strategies and agents. <i>National Journal of Maxillofacial Surgery</i> , 2022, 13, 322.	0.1	1
634	Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. , 2023, 20, 694-713.		8
635	TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
640	Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients. <i>International Review of Cell and Molecular Biology</i> , 2024, , 181-206.	1.6	0
655	PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade. <i>British Journal of Cancer</i> , 2023, 129, 1409-1416.	2.9	4